Comparison
NMN vs CBD (Cannabidiol)
NMN
Nicotinamide mononucleotide, NAD+ precursor. Studied for cellular aging and metabolic health.
CBD (Cannabidiol)
Non-psychoactive cannabinoid from hemp. Anxiolytic, anti-seizure, anti-inflammatory. The supplement market has grown explosively despite mixed evidence base.
| Field | NMN | CBD (Cannabidiol) |
|---|---|---|
| Category | neuroprotective | neuroprotective |
| Dose range | 250–1000mg | 25–600mg |
| Half-life | – | – |
| Onset | – | – |
| Evidence | EVIDENCEB | EVIDENCEB |
| Safety | ●●●●● | ●●●●○ |
| Legal (US) | USOTC | USOTC |
| PubMed refs | 600 | 6800 |
The comparison in plain English
Auto-generated from dataNMN and CBD (Cannabidiol) are both in the neuroprotective category respectively. NMN Nicotinamide mononucleotide, NAD+ precursor. CBD (Cannabidiol) Non-psychoactive cannabinoid from hemp.
Bottom line
NMN (evidence B, safety 5/5) matches the evidence base of CBD (Cannabidiol) (evidence B, safety 4/5). NMN has the slightly cleaner safety profile. For users new to either, the higher-evidence option is the safer first try.
Choose NMN if
NMN is the better fit when your goal aligns with its mechanism (Direct precursor to NAD+, one biosynthetic step closer than nicotinamide riboside, bypassing the NRK1/NRK2 enzymatic step) and the dose range (250–1000mg) suits your protocol. Half-life is –h.
Choose CBD (Cannabidiol) if
CBD (Cannabidiol) is the better fit when your goal aligns with its mechanism (Modulates the endocannabinoid system through indirect mechanisms, CBD doesn't bind CB1 or CB2 receptors directly like THC does) and the dose range (25–600mg) suits your protocol. Half-life is –h.